



# Treatment Options for Rheumatoid Arthritis: Effectiveness and Value

---

## Draft Voting Questions for March 24, 2017 Public Meeting

These questions are intended for the deliberation of the New England CEPAC voting body at the public meeting.

**Patient population for all voting questions:** Patients ages 18 and older with moderately-to-severely active rheumatoid arthritis and inadequate response to or intolerance of conventional DMARDs.

### Comparative Effectiveness of Targeted Immune Modulators as Monotherapy:

1. Is the evidence adequate to demonstrate that the net health benefit of tocilizumab monotherapy is superior to that provided by adalimumab monotherapy?

Yes                      No

2. Is the evidence adequate to demonstrate that the net health benefit of sarilumab monotherapy is superior to that provided by adalimumab monotherapy?

Yes                      No

3. Is the evidence adequate to demonstrate that the net health benefit of tofacitinib monotherapy is superior to that provided by adalimumab monotherapy?

Yes                      No

4. Is the evidence adequate to demonstrate that the net health benefit of baricitinib monotherapy is superior to that provided by adalimumab monotherapy?

Yes                      No

### Comparative Effectiveness of Targeted Immune Modulators in Combination With cDMARDs:

5. Is the evidence adequate to demonstrate that the net health benefit of tocilizumab +cDMARD therapy is superior to that provided by adalimumab + cDMARD therapy?

Yes                      No

6. Is the evidence adequate to demonstrate that the net health benefit of sarilumab +cDMARD therapy is superior to that provided by adalimumab + cDMARD therapy?

Yes                      No

7. Is the evidence adequate to demonstrate that the net health benefit of tofacitinib +cDMARD therapy is superior to that provided by adalimumab + cDMARD therapy?

Yes                      No

8. Is the evidence adequate to demonstrate that the net health benefit of baricitinib +cDMARD therapy is superior to that provided by adalimumab + cDMARD therapy?

Yes                      No

### Comparative Value of Targeted Immune Modulators (TIM):

9. Given the available evidence on comparative effectiveness and incremental cost-effectiveness, and taking into account other benefits, disadvantages, and contextual considerations, what is the long-term value for money for all TIMs with or without cDMARD therapy in comparison to cDMARD therapy?

*Low*

*Intermediate*

*High*